Visual Frailty in Ageing
Launched by UNIVERSITY OF EDINBURGH · Sep 18, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The "Visual Frailty in Ageing" clinical trial is studying a new way to understand and measure something called visual frailty in older adults, specifically those aged 60 and above who have advanced Age-related Macular Degeneration (AMD). This study aims to find out how factors like vision quality, reading ability, mental health, and other health conditions are connected to visual frailty. Participants will have their vision and reading skills tested, and researchers will gather information about their overall health and well-being through phone calls with them and their family members.
To be eligible for this study, participants must be residents of Scotland, aged 60 or older, and currently receiving treatment for AMD at the Princess Alexandra Eye Pavilion for at least six months. They should also be able to understand and agree to participate in the study. Notably, anyone who has had certain eye surgeries or cannot communicate in English will not be included at this stage, but plans are in place to include non-English speakers later. This study will help improve how we monitor and support the visual health of older people as they age.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants should be residents of Scotland aged 60 years and above with a known diagnosis of advanced AMD.
- • The patients should be receiving treatment from Princess Alexandra Eye Pavilion (PAEP) for at least 6 months and should be responding positively to the treatment. This is to rule out poor results due to either not receiving medication or non-compliance.
- • The participants should be able to provide informed consent before taking part in the study.
- Exclusion Criteria:
- • Participants who cannot speak and read English language will not be included in this pilot study. However, non-English speakers will be included in the future together with interpreters at the validation phase of the developed tool.
- • Participants who have undergone invasive ocular surgery like cataract extraction in their previous visit.
- • The potential participants who fail to provide or do not provide informed consent will not be included in the study.
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, Scotland, United Kingdom
Edinburgh, , United Kingdom
Patients applied
Trial Officials
Peter Cackett
Principal Investigator
Princess Alexandra Eye Pavilion
Ian Underwood
Study Director
School of Engineering, University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported